Adicet Bio Company
resTORbio was a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of aging-related diseases. They developed RTB101, a small molecule product drug candidate, and a potent inhibitor of target of rapamycin complex 1 (TORC1). RTB101 was developed as a respiratory tract infection drug. In september 2020 they merged with another company and now trade under the name Adicet Bio, Inc. where RTB101 continues to be developed under the new company name.